| Cell line name |
H69/VP |
|---|
| Accession |
CVCL_0B23 |
|---|
| Resource Identification Initiative |
To cite this cell line use: H69/VP (RRID:CVCL_0B23) |
|---|
| Comments |
Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16). |
|---|
| Sequence variations |
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Lung small cell carcinoma (NCIt: C4917)
Small cell lung cancer (ORDO: Orphanet_70573)
Derived from metastatic site: Pleural effusion. |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1579 (NCI-H69) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
55Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=8784480; DOI=10.1159/000227600
Shinohara A., Shimizu E., Takada M., Sone S.
Lack of c-mpl proto-oncogene transcripts and growth-stimulatory effects of thrombopoietin on human small cell lung cancer cell lines.
Oncology 53:426-434(1996) PubMed=9062409; DOI=10.1038/bjc.1997.154
Jensen P.B., Holm B., Sorensen M., Christensen I.J., Sehested M.
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Br. J. Cancer 75:869-877(1997) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54872203
|
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2015 |
|---|
| Last entry update | 15-Dec-2022 |
|---|
| Version number | 11 |
|---|
